Management of Castration Resistant Prostate Cancer (eBook)

Fred Saad, MD, FRCSProfessor and Chief of Urology, Director of GU Oncology, University of Montreal Endowed Chair in Prostate Cancer, University of Montreal Hospital Center, Department of Surgery, Division of Urology, Montreal, Quebec, Canada.Mario A. Eisenberger, MDR. Dale Hughes Professor of Oncology and Urology, The Johns Hopkins University, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.

Part I. Castrate-Resistant Prostate Cancer: Clinical and Biological ConsiderationsChapter 1 - Introduction - Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities - Mario A. Eisenberger and Fred SaadChapter 2. Evolution of Clinical States and the Castration Resistant Clinical Paradigm - Tian Zhang and Andrew J. ArmstrongChapter 3. Molecular Mechanisms of Prostate Cancer Progression after Castration - William G. Nelson and Kenneth J. PientaChapter 4. New Imaging Modalities - Steve Y. Cho, Seyed S. Dianat and Katarzyna MacuraPart II. TREATMENT - The Androgen Receptor Signaling Axis biology and Therapeutic Opportunities, Systemic Chemotherapy, Immunotherapy, Bone Targeted Approaches and RadiopharmaceuticalsChapter 5. Androgen Receptor Biology in Castration Resistant Prostate Cancer - Heather H. Cheng and Bruce MontgomeryChapter 6. The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer - Jarett L. Feldman, Dana Rathkopf and Michael J. MorrisChapter 7. Approaches Targeting Androgen Synthesis (CYP 17 inhibitors) - Adam Siegel and Charles J. RyanChapter 8. Cytotoxic Chemotherapy (Taxanes and Taxane Combinations) - Robert J. van Soest, Ellen S. de Morrée, Cora N. Sternberg and Ronald de WitChapter 9. The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer - Romulado Barroso-Sousa and Charles G. DrakeChapter 10. Bone Targeted Therapy: Rationale and Current Status - Benjamin A. Gartrell and Fred SaadChapter 11. Radium-223 and Other Radiopharmaceuticals in Prostate Cancer - Oliver Sartor and Brian LewisPart III. New Drug Development: Clinical Trials Design in CRPCChapter 12. Introduction - Aurelius Omlin, Carmel Pezaro and Johann S. de BonoChapter 13. Phase I/II targeted treatments - Aurelius Omlin, Carmel Pezaro and Johann S. de BonoChapter 14. Defining Clinical Endpoints in Castration-resistant Prostate Cancer - Jorge A. Garcia and Robert DreicerPart IV. New Drug Development: Specific TargetsChapter 15. Angiogenesis Inhibition in Castration Resistant Prostate Cancer - Daniel J. George, William Kelly and Aaron MitchellChapter 16. Co-targeting Adaptive Survival Pathways - Amina Zoubeidi and Martin GleaveChapter 17. Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer - Hans J. Hammers and Emmanuel S. AntonarakisChapter 18. PARP Inhibitors - Joaquin Mateo, Timothy A. Yap and Johann S. De BonoChapter 19. Targeting C-Met/VEGF in Castration Resistant Prostate Cancer - Petros D. Grivas and David C. SmithChapter 20. Epigenetics in Castration Resistant Prostate Cancer - Leigh Ellis, Sheng-Yu Ku, Elena Lasorsa and Roberto PiliChapter 21. Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype - Himisha Beltran, Gurveen Kaur, Myriam Kossai, David M. Nanus and Scott T. TagawaPart V. Clinical Management AspectsChapter 22. Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management - Channing J. Paller and Thomas J. SmithChapter 23. Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development - Jacob A. Martin and William K. Oh